Literature DB >> 31335982

A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia.

Andrea Visentin1,2, Marina Deodato3, Francesca R Mauro4, Francesco Autore5, Gianluigi Reda6, Candida Vitale7, Stefano Molica8, Gian Matteo Rigolin9, Francesco Piazza1,2, Laura Cesini4, Alessandra Tedeschi3, Luca Laurenti5, Ramona Cassin6, Marta Coscia7, Antonio Cuneo9, Robin Foà4, Gianpietro Semenzato1,2, Livio Trentin1,2.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31335982     DOI： 10.1002/hon.2655

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN： 0278-0232            Impact factor:   5.271


× No keyword cloud information.
  4 in total

1.  Response to Comment on: "Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients".

Authors:  Jennifer R Brown
Journal:  Haematologica       Date:  2022-06-01       Impact factor: 11.047

2.  Anti-cancer Drugs Associated Atrial Fibrillation-An Analysis of Real-World Pharmacovigilance Data.

Authors:  Javaria Ahmad; Aswani Thurlapati; Sahith Thotamgari; Udhayvir Singh Grewal; Aakash Rajendra Sheth; Dipti Gupta; Kavitha Beedupalli; Paari Dominic
Journal:  Front Cardiovasc Med       Date:  2022-04-15

Review 3.  Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.

Authors:  Joerg Herrmann
Journal:  Nat Rev Cardiol       Date:  2020-03-30       Impact factor: 32.419

Review 4.  From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance.

Authors:  Andrea Visentin; Stefano Pravato; Francesca Castellani; Marta Campagnolo; Francesco Angotzi; Chiara Adele Cavarretta; Alessandro Cellini; Valeria Ruocco; Alessandro Salvalaggio; Alessandra Tedeschi; Livio Trentin; Chiara Briani
Journal:  Cancers (Basel)       Date:  2022-03-18       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.